Because psoriasis is associated with an increased incidence of some malignancies such as skin cancer, we assessed the malignancy rates in multiple clinical studies of brodalumab, a fully human anti–interleukin-17 receptor A monoclonal antibody efficacious for the treatment of moderate-to-severe plaque psoriasis.

We found that brodalumab appears to have a low carcinogenic risk of malignancy on the basis of an analysis of > 8000 patient-years of exposure.